Blog | HemaCare

An independent study carried out at a Cellular Technology Ltd. cites using HemaCare PBMCs in their efforts to replicate physiological B cell activation in an assay format. [1]

Memory B cells function as the foundation of the adaptive immune system, creating a physiological catalogue of foreign antigens that can be used to “recognize” invading pathogens and trigger an immune response. Memory B cells can survive for decades, creating long-term protection against diseases that have been encountered previously.

Cell therapy starting materials sourced from HemaCare are being used to support studies focused on the selective expansion of tumor-specific T cells.

In a recent article, ^[1] researchers at a Cambridge, MA biotech company describe their work with a fusion protein designed to specifically activate and expand killer T cells that recognize human papilloma virus associated (HPV+) head and neck cancer cells.

In a recent study, scientists at UCLA medical school cited using HemaCare sourced PBMCs for their research into a novel cancer immunotherapy strategy. ^[1]

This promising new strategy is based on cellular structures known as exosomes, which are small membrane-bound packets used to deliver protein “messages” from cell to cell. Because exosomes are known to facilitate cell-to-cell communications, researchers were keen to figure out whether they could be used to communicate the information immune cells need to target cancer.

A collaborative research effort on the part of 3 top-tier pharmaceutical companies cite using HemaCare sourced healthy donor PBMCs for their work on developing an allogeneic CAR T cell therapy. ^[1] CAR T therapies are among the most promising new cancer treatments approved by the FDA. These therapies have had remarkable success rates in people suffering from aggressive leukemia and lymphoma, who would otherwise be left without treatment options. The number of people who can be treated with this type of therapy is limited, however. CAR T treatment is an autologous therapy, relying on collecting and modifying a patient’s own T cells to fight their disease. Since cancer patients often suffer from a compromised immune system, it’s quite difficult to collect enough healthy T cells for treatment. Several research groups have been looking for a way to make an allogeneic CAR T cell treatment, in which T cells can be sourced from healthy donors.

New research may have found a way to make the difficult task of diagnosing ME/CFS much easier through the identification of a new reliable biomarker.

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic condition causing extreme fatigue and debilitation, sleep problems, issues with mentation, and other symptoms. The cause is unknown, but immune system alterations, stress, or infectious processes may be associated with the onset of the condition. The Institute of Medicine (IOM) reported in 2015 that over 800,000 (and perhaps up to 2.5 million) Americans have ME/CFS, with most cases going undiagnosed. The diagnostic challenge is well known, and there has not been a specific test that can confirm ME/CFS. Usually, a number of other conditions must be ruled out before making a diagnosis of ME/CFS.